Recently, many molecular-targeted agents have been tried to improve HCC survival, such as Erlotinib targeting EGFR, RAD001 and CCI-779 targeting PI3K/AKT/MTOR, Lapatinib targeting HER2 and so on, however, only Sorafenib, which has multiple molecular targets, was approved by FDA in treating HCC [17–21]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.